Q-omics provides the consensus-scored LRRC7 profile across patient tissues and cancer cell-line models. LRRC7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LRRC7 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, LRRC7 RNA expression shows 19,444 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, THCA, and UVM as cancer lineages where LRRC7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC7 survival associations across molecular data types. LRRC7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (12) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC7 RNA expression–survival associations across cancer types. High LRRC7 expression shows unfavorable associations in KICH, HNSC and UCEC, but favorable associations in BLCA, PAAD and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for LRRC7 RNA expression.
This table summarizes LRRC7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC7 shows lower tumor expression in THCA, COAD, KICH, KIRP and READ and higher tumor expression in KIRC. The THCA box plot shows higher LRRC7 RNA expression in normal versus tumor tissue (log2 FC = −1.184, t-test p < 0.001).
This table shows molecular features associated with LRRC7 in patient tissues and cancer cell lines. In patient samples, LRRC7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
